Photo of Technology Transactions

Technology Transactions


Smith Anderson's intellectual property lawyers work with businesses to develop, protect and promote their knowledge, discoveries and innovations. Our attorneys support their clients engaged in transactions to acquire, sell, finance, support, develop, and monetize key intellectual property assets. This includes a variety of transaction arrangements, including mergers and acquisitions, strategic licensing and technology transfer, partnering and alliances, patent and trademark preparation and prosecution, M&A due diligence, sponsored research, financing and manufacturing/sourcing arrangements.

We also help clients to build and protect their brands through strategic development, maintenance and enforcement of trademark and service mark portfolios. We regularly assist clients with complex information privacy and data security issues, including breach notice and incident response. We also work with clients to resolve intellectual property-related disputes, such as patent and trade secret litigation, trademark litigation and oppositions, copyright litigation, licensing disputes and internet disputes.

Our intellectual property clients range from publicly-traded companies and well-established privately-held businesses to start-ups, emerging companies and university spin outs. We provide intellectual property services to clients in a wide array of industries, including: life sciences, software, health care, pharmaceuticals, telecommunications, video games, electronics, banking, building materials, eCommerce, industrial machinery, consumer goods and more. As a full-service firm, we also advise our clients on labor and employment matters, employee benefits, tax strategies, governmental relations, real estate and other business-related matters. 



  • Represented a global solid state LED lighting and semiconductor manufacturing company in connection with its $850 million sale of assets to a publicly traded German semiconductor company. The transaction was terminated before completion due to regulatory considerations.
  • Advised a worldwide interactive entertainment and gaming company in the sale of a game franchise to a global computer software company and assisted in the development of an innovative licensing model for the client's video game development software.
  • Prepared a negotiation “toolkit” establishing contracting parameters and fallback positions to allocate and address intellectual property and data-related risks in a global technology company’s software-as-a-service and data hosting arrangements.
  • Assisted a leading corporate travel management firm in the U.S. with drafting and negotiation of a services agreement with a creative consulting firm for a brand identity refresh and related website redesign and development services.
  • Representation of a leading provider of wireless transmission systems in its divestiture of an integrated communications network management software platform and related assets to a network management software company.
  • Assisted an e-commerce vendor in developing terms of use, privacy policy and consignment and sale agreements for use in an online business.
  • Represented a leading fuel pump supplier in establishing a technology, sales and service partnership with a leading payment system supplier to develop next-generation payment and media technologies for the retail petroleum industry.
  • Conducted training sessions for the legal department of one of the world’s largest software and technology service providers, providing negotiation and risk allocation strategies for the company’s technology license and services arrangements, covering complex indemnity provisions, license provisions and related risk allocation issues.
  • Lead counsel to a venture capital-funded genome editing company in a worldwide partnership, worth up to $1.6 billion, including an upfront payment of $105 million, with a global, publicly-traded pharmaceutical company to develop and commercialize allogeneic chimeric antigen receptor (CAR) T cell therapies for multiple cancers. The transaction was awarded the 2016 Life Science sector Deals of Distinction™ award by the Licensing Executives Society.
  • Represented an international health care group and its U.S. specialty pharmaceutical company subsidiary in obtaining multinational license rights to three cardiovascular drugs from a large public pharmaceutical company for $264 million in cash at closing, up to $480 million in milestone and royalty payments, and the assumption of up to $50 million in milestone payment obligations.
  • Over 200 AgTech research, development, license, acquisition and collaboration agreements, totaling in excess of $2 billion in cumulative value plus royalties, including over 50 transactions involving five of the six largest agriculture companies in the world.
  • Represented a venture capital-funded biotechnology company that uses the plant-associated microbiome to create innovative agricultural products in an R&D collaboration with a leading global agricultural biotechnology company for discovery, development and commercialization of crop trait products.
  • Represented a leading genome editing company in over a dozen research, collaboration, licensing and development agreements ranging from human therapeutics to row plant crop applications and specialty plant crop applications.
  • Represented university spin-outs in licensing foundational technology from universities such as Harvard University/Massachusetts General Hospital, MIT, Caltech, Columbia University, Duke University, Johns Hopkins University, University of California System, Duquesne University, University of North Carolina at Chapel Hill, North Carolina State University, East Carolina University, Dartmouth College, University of Pennsylvania, University of Virginia and Virginia Tech, among others.
  • Dozens of worldwide and territory-specific pharmaceutical, biologic and medical device research, development, license, collaboration and acquisition agreements, for therapeutic areas ranging from immuno-oncology to CNS disorders, dermatology, ophthalmology, cardiovascular, rare disease, oncology, vaccines, and others.



  • Licensing and technology transfer
  • Mergers and acquisitions
  • Domestic and international patent and trademark preparation and prosecution
  • Patent opposition and post-grant proceedings, including ex parte reexamination and America Invents Act (AIA) proceedings such as inter partes review (IPR), post-grant review (PGR), and covered business method (CBM) review
  • Research, development and commercialization collaborations
  • Partnering, strategic alliance and joint venture arrangements
  • Product and intellectual property acquisitions and divestitures
  • Information privacy and security matters, including policies and procedures, breach notice and incident response, investigations and corporate transactions
  • Trademark and service mark matters, including strategic portfolio development, prosecution, maintenance, licensing and enforcement
  • Trademark opposition and cancellation proceedings
  • Strategic patent enforcement programs
  • Patent, trademark and copyright litigation
  • Trade secret disputes
  • Advertising, unfair competition and social media disputes

News & Publications



Events & Webinars


Practice Contacts

Sign Up to Receive Updates and Alerts

Interested in Learning More?

Contact Us ›

Back to Page